Javascript is required for this site to function, please enable.
Page: Your Views
1. Please indicate your level of agreement with the following statements regarding the dissemination of off-label drug information by the pharmaceutical industry.
 answered question61
 
skipped question
0
 Strongly DisagreeDisagree SomewhatNeither Agree nor DisagreeAgree SomewhatStrongly AgreeRating
Average
Rating
Count
Under NO circumstances should drug companies be permitted to hand out off-label information -- including peer-reviewed journal articles -- to physicians and other health care professionals.31.1% (19)23.0% (14)6.6% (4)19.7% (12)19.7% (12)-0.2661
As in the old rule, a drug company should be permitted to hand out such information IF the information is first reviewed by the FDA and the company declares that it intends to submit an application for FDA approval of the off-label use (ie, perform clinical trials).8.2% (5)32.8% (20)8.2% (5)24.6% (15)26.2% (16)0.2861
FDA is forced to relax the rules because not to do so is an infringement of commercial free-speech rights.36.1% (22)9.8% (6)27.9% (17)13.1% (8)13.1% (8)-0.4361
The new rule will stop pharmaceutical companies from underwriting expensive trials to confirm new drug uses.31.1% (19)31.1% (19)6.6% (4)24.6% (15)6.6% (4)-0.5661
Because the FDA is so slow in assessing drug and device benefits, it is imperative that drug companies be able to hand out medical journal articles so that doctors can learn immediately about life-saving uses.31.1% (19)16.4% (10)4.9% (3)27.9% (17)19.7% (12)-0.1161
Doctors have many other sources of information about off-label use of drugs -- the Internet and their own journal subscriptions, for example -- and do not require that pharmaceutical companies provide this information to them.6.6% (4)19.7% (12)18.0% (11)23.0% (14)32.8% (20)0.5661
Since the FDA admitted that it did not really enforce the old requirements, it is also not likely to enforce the NEW requirements (ie, use of peer-reviewed articles only, warning label on articles). Consequently, this gives the drug industry virtual free reign to do off-label promotion.24.6% (15)14.8% (9)13.1% (8)19.7% (12)27.9% (17)0.1161

2. OPTIONAL: Please provide any further comments you may have regarding any of the issues highlighted in the above comments.
 answered question20
 
skipped question
41
 Response
Count
 20

Page: Questions About You
3. Which best describes your professional or organizational affiliation (please pick only one even if more than one applies):
 answered question61
 
skipped question
0
 Response
Percent
Response
Count
Medical School/Academia
3.3%2
Medical Professional Society 0.0%0
Advertising agency
1.6%1
Consumer or patient
11.5%7
Independent Consultant/Consulting Company
18.0%11
Marketing Communications or PR agency
1.6%1
Medical Education Communications Company (MECC)
3.3%2
Pharmaceutical, biotech, or drug device company
31.1%19
Physician, nurse, or other healthcare professional
6.6%4
Publishing/Media
8.2%5
Other (please specify) 0.0%0
Other (please describe)
 
14.8%9

4. Please indicate how supportive you are of the pharmaceutical industry in general.
 answered question60
 
skipped question
1
 Very SupportiveSomewhat SupportiveNeutralSomewhat Unsupportivevery UnsupportiveRating
Average
Rating
Count
In general, I am:41.7% (25)23.3% (14)13.3% (8)13.3% (8)8.3% (5)0.7760

Page: Opt In Choice
5. OPTIONAL: If your comments are quoted in Pharma Marketing News and you would like attribution, please provide the following information. We will contact you about your comments and give you a chance to approve quotes before they are published. You must supply all contact information, including your email address, for us to do this. This information is NOT shared with third parties and will only be used to contact you about your responses to this survey. LEAVE THIS BLANK IF YOU WISH TO REMAIN ANONYMOUS.
 answered question10
 
skipped question
51
 Response
Percent
Response
Count
Name
 
100.0%10
Job Title
 
70.0%7
Company
 
80.0%8
Phone
 
60.0%6
E-mail Address
 
90.0%9

Find...
Show replies
Hide replies